ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Decline in Short Interest

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 360,300 shares, a drop of 42.6% from the December 31st total of 628,000 shares. Based on an average daily volume of 266,100 shares, the days-to-cover ratio is currently 1.4 days. Approximately 3.2% of the company’s stock are short sold.

ABVC BioPharma Price Performance

Shares of NASDAQ ABVC opened at $0.54 on Wednesday. The stock has a market capitalization of $6.94 million, a P/E ratio of -0.62 and a beta of 0.70. The company has a 50-day moving average price of $0.54 and a 200-day moving average price of $0.62. ABVC BioPharma has a 1 year low of $0.41 and a 1 year high of $1.73.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.